Only four therapeutics are currently licensed on the European and US markets to treat AD-related symptoms (Figure 1): the acetylcholine esterase (AChE) inhibitors donepezil (1), galantamine (2), and rivastigmine (3), as well as the N-methyl-D-aspartate (NMDA) receptor antagonist memantine (4). This evidence concerns the gene ACHE and Alzheimer disease.